Catalyst Pharmaceuticals Inc., of Coral Gables, Fla., reported fourth-quarter and full-year 2019 revenues for Lambert-Eaton myasthenic syndrome drug Firdapse (amifampridine) totaling $30.1 million and $102.3 million, respectively. For the full year 2020, the company reiterated revenue guidance in the range of $135 million to $155 million. It also reassured investors it was well-stocked for anticipated contingencies and has “more than an adequate supply” of Firdapse through the end of this year. For 2019, Catalyst reported net income of $31.9 million, or 31 cents per basic share, vs. a net loss of $34 million, or 33 cents per basic share, for 2018. As of Dec. 31, the company had $94.5 million in cash and investments. Shares of Catalyst (NASDAQ:CPRX) closed March 17 at $2.89, up 28 cents.